Nova Eye Medical Restricted (ELXMF) Q2 2026 Gross sales/Buying and selling Name Transcript

Mark Flynn
Investor Relations

Good morning, everybody, and thanks for becoming a member of us right now. This session will cowl Nova Eye Medical’s December 2025 quarterly gross sales outcomes. And as we have acknowledged in our ASX releases, it was a document quarter for the corporate, which we’re very happy with. We run via our efficiency highlights, what drove the outcome and the priorities of the yr forward. As all the time, you are welcome to submit any questions. I’ve obtained many already. Tom and I’ll look to handle on the finish of the session.

However now I am going to simply cross straight over to Tom Spurling, our Managing Director, and he’ll take you thru our potential gross sales efficiency and likewise the outlook for this yr. So over to you, Tom.

Thomas Spurling
MD & Govt Director

Thanks, Mark. So welcome, everyone. Thanks for tuning in. 90 registrations as of this morning, which is fantastic. It is — our mission is to — effectively, what we’re aiming with this session is to maintain our shareholders proper updated with what is going on on as a result of we’re a fast-growing firm, and the information is sweet. So we’ll get proper into it.

This is our disclaimer. Simply a few of you’d have seen this slide earlier than, I do not need to underestimate the significance of the market we’re in. Interventional glaucoma. The concept is that the energetic engagement or surgical engagement to vary the illness trajectory earlier within the illness state and making an attempt to get folks off drops, which usually lead to a poor high quality of life outcomes. The info now we have reveals pharma spend is falling barely. It is a huge market, nevertheless it’s falling barely. And surgical units are rising.